文献速递甲状腺与浅表头颈介入US

超声引导下射频消融与甲状腺腺叶切除术治疗T1bN0M0甲状腺乳头状癌的比较

Comparison of ultrasound-guided radiofrequency ablation versus thyroid lobectomy for T1bN0M0 papillary thyroid carcinoma.
PubMed 文献 · Eur Radiol · 2022-07-27

该回顾性研究比较了283例单发T1bN0M0甲状腺乳头状癌患者接受射频消融(91例)或甲状腺腺叶切除术(192例)的临床结局。中位随访50.4个月,两组在局部肿瘤进展、淋巴结转移、复发肿瘤、持续肿瘤及无复发生存率方面无显著差异;射频消融组住院时间更短、手术时间更短、估计失血量更少、费用更低、并发症率更低。作者认为经严格评估后射频消融可能是有前景的可行替代方案。

要点

  • 中位随访50.4个月,射频消融与腺叶切除的局部肿瘤进展率分别为4.4%与3.6%,无显著差异。
  • 两组无复发生存率分别为95.6%与96.4%,无显著差异。
  • 射频消融组住院时间0天、手术时间5.6分钟、估计失血量0 mL、费用1972.5美元,均低于腺叶切除组。

核心结论

  • 对于T1bN0M0甲状腺乳头状癌,射频消融与甲状腺腺叶切除术在局部肿瘤进展和无复发生存方面4年临床结局相当,射频消融可能是有前景的可行替代方案,但需严格评估后选择患者。

研究设计与样本

  • 回顾性研究,纳入2014年5月至2018年11月接受治疗的283例单发T1bN0M0甲状腺乳头状癌患者,其中射频消融组91例、甲状腺腺叶切除组192例,治疗后定期随访。

关键影像表现/征象

  • 两组局部肿瘤进展率分别为4.4%与3.6%,无显著差异(p=1.000)。
  • 两组淋巴结转移率分别为1.1%与2.1%,无显著差异(p=0.917)。
  • 两组复发肿瘤率分别为2.2%与1.6%,无显著差异(p=1.000)。
  • 两组持续肿瘤率分别为1.1%与0%,无显著差异(p=0.146)。
  • 两组均未检测到远处转移。

诊断标准与关键数值

  • 中位随访时间50.4个月(四分位距18.0个月)。
  • 射频消融组与腺叶切除组的无复发生存率分别为95.6%与96.4%,无显著差异(p=0.816)。
  • 射频消融组与腺叶切除组的住院时间分别为0天与7.0天(四分位距3.0天),p<0.001。
  • 射频消融组与腺叶切除组的手术时间分别为5.6分钟(四分位距2.9分钟)与90.0分钟(四分位距38.5分钟),p<0.001。
  • 射频消融组与腺叶切除组的估计失血量分别为0 mL与20 mL(四分位距20 mL),p<0.001;费用分别为1972.5美元(四分位距0.1美元)与2362.4美元(四分位距1009.3美元),p<0.001;并发症率分别为0与12/192(6.3%),p=0.015。

临床应用与阅片要点

  • 对于经严格评估选择的T1bN0M0甲状腺乳头状癌患者,射频消融可能作为腺叶切除术的可行替代方案。
  • 射频消融组无患者接受延迟手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate and compare the clinical outcomes between radiofrequency ablation (RFA) and thyroid lobectomy (TL) for T1bN0M0 papillary thyroid carcinoma (PTC).

METHODS: This retrospective study evaluated 283 patients with solitary T1bN0M0 PTC treated with RFA (RFA group, 91 patients) or TL (TL group, 192 patients) from May 2014 to November 2018. The patients were regularly followed up after treatment. Local tumor progression, lymph node metastasis (LNM), recurrent tumor, persistent tumor, recurrence-free survival (RFS), treatment variables (hospitalization, procedure time, estimated blood loss, and cost), complication, and delayed surgery were compared.

RESULTS: During the follow-up (median [interquartile ranges], 50.4 [18.0] months), no significant differences were found in the local tumor progression (4.4% vs 3.6%, p = 1.000), LNM (1.1% vs 2.1%, p = 0.917), recurrent tumor (2.2% vs 1.6%, p = 1.000), persistent tumor (1.1% vs 0%, p = 0.146), and RFS rate (95.6% vs 96.4%, p = 0.816) in the RFA and TL groups. Distant metastasis was not detected. Patients in the RFA group had a shorter hospitalization (0 vs 7.0 [3.0] days, p < 0.001), shorter procedure time (5.6 [2.9] vs 90.0 [38.5] min, p < 0.001), lower estimated blood loss (0 vs 20 [20] mL, p < 0.001), lower cost ($1972.5 [0.1] vs $2362.4 [1009.3], p < 0.001), and lower complication rate (0 vs 12/192 [6.3%], p = 0.015) than those in the TL group. No patients in the RFA group underwent delayed surgery.

CONCLUSIONS: This study revealed comparable 4-year clinical outcomes between RFA and TL for T1bN0M0 PTC in terms of local tumor progression and RFS. As a minimally invasive modality, RFA may be a promising feasible alternative to surgery for the treatment of T1bN0M0 PTC in selected patients after strict evaluation.

KEY POINTS: • No significant difference in local tumor progression and RFS was found between RFA and TL for T1bN0M0 PTC during a median follow-up period of 50.4 months. • Compared with TL, RFA led to a shorter hospitalization, lower estimated blood loss, lower cost, and lower complication rate. • RFA may be a promising feasible alternative to surgery for the treatment of T1bN0M0 PTC in selected patients after strict evaluation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yan, Li, Li, et al. Comparison of ultrasound-guided radiofrequency ablation versus thyroid lobectomy for T1bN0M0 papillary thyroid carcinoma. Eur Radiol. 2022. PMID: 35895122. doi:10.1007/s00330-022-08963-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。